SG Americas Securities LLC Makes New $444,000 Investment in BioLife Solutions, Inc. (NASDAQ:BLFS)

SG Americas Securities LLC purchased a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 19,512 shares of the medical equipment provider’s stock, valued at approximately $444,000.

A number of other institutional investors have also recently made changes to their positions in BLFS. Allspring Global Investments Holdings LLC purchased a new stake in shares of BioLife Solutions during the fourth quarter valued at approximately $76,000. Truist Financial Corp purchased a new stake in shares of BioLife Solutions during the first quarter valued at approximately $208,000. Handelsbanken Fonder AB purchased a new stake in shares of BioLife Solutions during the fourth quarter valued at approximately $257,000. Stansberry Asset Management LLC purchased a new stake in shares of BioLife Solutions during the fourth quarter valued at approximately $276,000. Finally, NorthCrest Asset Manangement LLC purchased a new stake in shares of BioLife Solutions during the first quarter valued at approximately $293,000. Hedge funds and other institutional investors own 83.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Cowen lowered their price objective on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. Oppenheimer upgraded shares of BioLife Solutions from a “market perform” rating to an “outperform” rating in a research report on Monday, April 25th. TheStreet downgraded shares of BioLife Solutions from a “c-” rating to a “d” rating in a research report on Tuesday, April 12th. Maxim Group lowered their price objective on shares of BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. Finally, Cowen lowered their price objective on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Insider Activity

In other news, CRO Marcus Schulz sold 4,600 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now directly owns 36,218 shares in the company, valued at approximately $725,446.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CRO Marcus Schulz sold 4,600 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total transaction of $92,138.00. Following the sale, the executive now directly owns 36,218 shares in the company, valued at approximately $725,446.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Greef Roderick De sold 9,158 shares of the firm’s stock in a transaction on Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total transaction of $144,604.82. Following the transaction, the chief operating officer now directly owns 124,458 shares of the company’s stock, valued at $1,965,191.82. The disclosure for this sale can be found here. Insiders have sold 19,678 shares of company stock worth $325,403 in the last three months. Company insiders own 5.90% of the company’s stock.

BioLife Solutions Stock Up 0.6 %

BLFS opened at $21.49 on Friday. The company has a current ratio of 3.39, a quick ratio of 2.53 and a debt-to-equity ratio of 0.01. BioLife Solutions, Inc. has a 1-year low of $10.40 and a 1-year high of $60.67. The company has a market capitalization of $911.39 million, a PE ratio of -61.40 and a beta of 1.99. The firm’s 50 day simple moving average is $15.94 and its two-hundred day simple moving average is $19.00.

BioLife Solutions (NASDAQ:BLFSGet Rating) last released its quarterly earnings results on Monday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $36.22 million during the quarter, compared to the consensus estimate of $37.87 million. BioLife Solutions had a negative return on equity of 6.24% and a negative net margin of 10.35%. During the same quarter in the previous year, the business posted $0.01 earnings per share. As a group, equities analysts forecast that BioLife Solutions, Inc. will post -0.67 EPS for the current year.

About BioLife Solutions

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating).

Institutional Ownership by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.